4586.T Stock - MedRx Co., Ltd
Unlock GoAI Insights for 4586.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $257.00M | $29.00M | $59.48M | $8.35M | $115.09M |
| Gross Profit | $219.19M | $26.00M | $10.45M | $6.09M | $111.18M |
| Gross Margin | 85.3% | 89.7% | 17.6% | 72.9% | 96.6% |
| Operating Income | $-793,000,000 | $-933,000,000 | $-1,098,820,000 | $-1,061,226,000 | $-1,130,420,000 |
| Net Income | $-806,000,000 | $-932,000,000 | $-1,111,150,000 | $-1,059,833,000 | $-1,114,645,000 |
| Net Margin | -313.6% | -3213.8% | -1868.0% | -12692.6% | -968.5% |
| EPS | $-18.54 | $-26.82 | $-43.81 | $-49.62 | $-68.61 |
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
Visit WebsiteEarnings History & Surprises
4586.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 8, 2025 | — | $-3.78 | — | — |
Q2 2025 | May 9, 2025 | — | $-9.04 | — | — |
Q1 2025 | Feb 14, 2025 | — | $-10.26 | — | — |
Q4 2024 | Nov 8, 2024 | — | $-5.64 | — | — |
Q3 2024 | Aug 9, 2024 | — | $1.60 | — | — |
Q2 2024 | May 10, 2024 | — | $-3.33 | — | — |
Q1 2024 | Feb 9, 2024 | — | $-6.81 | — | — |
Q4 2023 | Nov 10, 2023 | — | $-5.21 | — | — |
Q3 2023 | Aug 10, 2023 | — | $-5.61 | — | — |
Q2 2023 | May 12, 2023 | — | $-9.61 | — | — |
Q1 2023 | Feb 10, 2023 | — | $-17.21 | — | — |
Q4 2022 | Nov 11, 2022 | — | $-10.32 | — | — |
Q3 2022 | Aug 10, 2022 | — | $-7.49 | — | — |
Q2 2022 | May 13, 2022 | — | $-8.01 | — | — |
Q1 2022 | Feb 10, 2022 | — | $-16.12 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-9.20 | — | — |
Q3 2021 | Aug 10, 2021 | — | $-10.58 | — | — |
Q2 2021 | May 13, 2021 | — | $-13.37 | — | — |
Q1 2021 | Feb 10, 2021 | — | $-7.29 | — | — |
Q4 2020 | Nov 6, 2020 | — | $-16.33 | — | — |
Latest News
Frequently Asked Questions about 4586.T
What is 4586.T's current stock price?
What is the analyst price target for 4586.T?
What sector is MedRx Co., Ltd in?
What is 4586.T's market cap?
Does 4586.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4586.T for comparison